Research Use Only: Cagrilintide and semaglutide are sold exclusively for in vitro and licensed laboratory research. Neither compound, alone or in combination, is approved for human consumption or therapeutic use. This article is educational and does not constitute medical advice or a research protocol recommendation.
What "CagriSema" Refers To in the Research Literature
CagriSema is the research shorthand for a fixed 2.4 mg / 2.4 mg combination of cagrilintide, a long-acting amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist. The pairing did not arise from marketing convenience — it reflects a deliberate research question: what happens when two independent, non-redundant satiety pathways are activated at the same time in the same animal or subject?
Both compounds already have deep individual research records. Our semaglutide research overview and cagrilintide research overview cover the single-agent literature in detail. This article focuses specifically on what changes — mechanistically and in outcome data — when the two are studied together.
Two Distinct Receptor Systems, One Combined Signal
Semaglutide acts on the GLP-1 receptor, a G protein-coupled receptor expressed in the pancreas, hypothalamus, brainstem, and gut. Its research profile is well established: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction. See our cagrilintide mechanism of action page for the receptor-level detail on the amylin side.
Amylin receptors, the target of cagrilintide, are a structurally different class — heterodimers formed from the calcitonin receptor and receptor activity-modifying proteins (RAMPs). They sit heavily in the brainstem's area postrema and nucleus tractus solitarius, feeding a satiety signal into the brain through a route that only partially overlaps with GLP-1R signaling. Because native amylin is co-secreted with insulin from pancreatic beta cells, it is mechanistically tied to meal-related satiety in a way that is distinct from — not redundant with — the GLP-1 pathway.
The research premise behind studying the two together is straightforward: if the pathways are genuinely non-redundant, co-activation should produce an effect larger than either compound alone, rather than just a shifted dose-response curve on a single pathway.
Preclinical Rationale for Co-Agonism
The idea of combining amylin and GLP-1 receptor agonists predates cagrilintide and semaglutide specifically. Earlier rodent work pairing pramlintide (a shorter-acting amylin analog) with GLP-1-class compounds found that co-administration produced weight-loss effects well beyond what simple additive modeling would predict, even when neither compound was pushed past its own saturation point. That finding — synergy rather than simple addition — is the reason cagrilintide and semaglutide were subsequently engineered with matched half-lives (both roughly a week, via fatty-acid chain modification) so the combination could be dosed and studied on a single, practical once-weekly schedule.
Diet-induced obesity (DIO) rodent models treated with the combination have shown fat-mass-dominant weight reduction, with several studies reporting better preservation of lean tissue in combination-treated animals compared to GLP-1 monotherapy at matched degrees of weight loss — a detail researchers studying body composition endpoints track closely.
Human Research Data: The REDEFINE Program
The clinical-stage research on this combination is unusually well documented for a peptide combination. In REDEFINE 1, a Phase 3 trial randomizing 3,417 adults with obesity or overweight plus comorbidities, once-weekly CagriSema produced mean weight loss of 22.7% at 68 weeks among participants who adhered fully to treatment (the "trial product" estimand), versus 2.3% with placebo. Under the more conservative treatment-policy estimand — which counts everyone regardless of adherence — the figures were 20.4% versus 3.0% for placebo. Roughly 60% of participants lost at least 20% of body weight.
Those numbers came in below the ≥25% target Novo Nordisk had guided toward earlier in development, but they still outperformed semaglutide monotherapy data from separate trials, consistent with the additive/synergistic rationale described above. Novo Nordisk filed for regulatory approval in December 2025 based on this program. Researchers should treat these figures strictly as trial-reported reference points for understanding the combination's research trajectory — not as guidance applicable outside a regulated clinical protocol.
A separate arm of the REDEFINE program (REDEFINE 2) studied the combination in participants with type 2 diabetes, where the metabolic environment differs meaningfully from the general obesity population studied in REDEFINE 1, and reported comparatively lower — though still substantial — weight-loss figures.
How CagriSema Compares to Single-Agent and Multi-Receptor Research
Within the broader landscape of metabolic peptide research, CagriSema sits alongside — but is mechanistically distinct from — dual and triple incretin agonists like tirzepatide and retatrutide, which add GIP and glucagon receptor activity to a GLP-1 backbone rather than adding an amylin-pathway compound. Our GLP-1 receptor agonists in research overview lays out how these different multi-receptor strategies compare on paper. The short version: tirzepatide and retatrutide expand the incretin receptor set being activated, while CagriSema keeps a single incretin receptor (GLP-1R) but pairs it with an entirely separate hormonal system (amylin). Both strategies aim at the same synergy question from different mechanistic angles, which is part of why the two families of research programs are frequently referenced against each other in the literature. See also our direct cagrilintide vs. pramlintide comparison for how cagrilintide's engineering differs from its earlier-generation amylin-analog predecessor.
Research Design Considerations
Investigators designing protocols involving both compounds should treat them as two independently sourced research materials with distinct reconstitution and stability profiles rather than assuming a single combined product's handling characteristics apply to each. Our cagrilintide reconstitution and storage guide and the parallel semaglutide handling documentation are useful starting references. Purity verification via third-party COA should be obtained separately for each compound before any laboratory use — see cagrilintide purity testing for what to look for on a certificate of analysis.
Frequently Asked Questions
Is CagriSema a single compound?
No. It is a research term describing the co-administration of two separately sourced peptides — cagrilintide and semaglutide — typically at a matched 2.4 mg / 2.4 mg dose ratio in the trials that have studied it.
Why study amylin and GLP-1 agonism together instead of just increasing the semaglutide dose?
Preclinical and clinical data both suggest the two pathways engage different central circuits and produce effects larger than dose-escalating either pathway alone — the core synergy hypothesis behind the combination.
Are these compounds approved for human use?
No. Cagrilintide and semaglutide, individually or combined, are sold by V8 Peptides exclusively for licensed laboratory and in vitro research. Nothing in this article constitutes medical advice or a recommendation for human or animal use.
References
- Novo Nordisk. REDEFINE 1 Phase 3 trial results, obesity/overweight population, 68-week data.
- Enebo LB, Berthelsen KK, Kankam M, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management." The Lancet. 2021;397(10286):1736-1748.
- Enebo LB, et al. Phase 2 CagriSema (SCALE-adjacent) dose-finding research, Novo Nordisk clinical program.
- Roth CL, Perez FA, Whitlock KB, et al. "Amylin receptor and GLP-1 receptor co-agonism in rodent models of diet-induced obesity." Preclinical metabolic research literature.
Written and reviewed by the V8 Peptides Research Team. All compounds referenced are sold for research purposes only. Nothing in this article constitutes medical advice or a recommendation for human use.
Related reading: Semaglutide vs. Tirzepatide · Retatrutide vs. Tirzepatide · GLP-1 Receptor Agonists in Research